OKYO Pharma LTD: OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial Evaluating Efficacy and Safety of OK-101 in Patients with Dry Eye Disease
Trial designed with pre-specified primary efficacy endpoints discussed previously with FDAIf successful, this phase 2 trial may serve as one of the two required phase 3 studies necessary to support FDA